A 55-year-old woman with prediabetes experienced paradoxical glycemic deterioration within one month of starting semaglutide 0.25 mg weekly, with fasting glucose rising from 107 to 169 mg/dL and HbA1c increasing from 6.0% to 6.6% despite 4 kg weight loss. Investigation revealed a 4×3 cm pancreatic adenocarcinoma with liver metastases. This case illuminates a critical clinical pattern where GLP-1 receptor agonists may inadvertently expose occult malignancies through unexpected metabolic responses. While extensive research confirms no causal link between semaglutide and pancreatic cancer, this finding suggests the drug's glycemic effects could serve as an early detection mechanism for existing tumors. The phenomenon likely reflects how pancreatic cancer disrupts normal glucose homeostasis, becoming more apparent when semaglutide's expected benefits fail to materialize. For clinicians prescribing these increasingly popular medications, atypical early responses—particularly worsening glycemia during initial dosing—warrant heightened surveillance. This represents neither a safety concern nor contraindication for semaglutide use, but rather an opportunity for earlier cancer detection in a notoriously late-diagnosed malignancy.